RVW Wealth LLC Has $2.59 Million Stock Holdings in Eli Lilly and Company $LLY

RVW Wealth LLC grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 81.2% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 2,160 shares of the company’s stock after acquiring an additional 968 shares during the quarter. RVW Wealth LLC’s holdings in Eli Lilly and Company were worth $2,591,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of LLY. Elmwood Wealth Management Inc. increased its position in shares of Eli Lilly and Company by 5.5% in the second quarter. Elmwood Wealth Management Inc. now owns 879 shares of the company’s stock worth $1,055,000 after purchasing an additional 46 shares during the period. Elevation Wealth Partners LLC lifted its position in Eli Lilly and Company by 155.1% during the second quarter. Elevation Wealth Partners LLC now owns 1,388 shares of the company’s stock worth $1,665,000 after purchasing an additional 844 shares during the period. Czech National Bank lifted its position in Eli Lilly and Company by 4.3% during the second quarter. Czech National Bank now owns 225,167 shares of the company’s stock worth $270,072,000 after purchasing an additional 9,355 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in Eli Lilly and Company by 8.4% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 149,389 shares of the company’s stock worth $179,182,000 after buying an additional 11,558 shares in the last quarter. Finally, Apella Capital LLC grew its stake in Eli Lilly and Company by 3.4% during the second quarter. Apella Capital LLC now owns 4,276 shares of the company’s stock worth $5,283,000 after buying an additional 139 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday. Sanford C. Bernstein increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. Wall Street Zen cut shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 18th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,293.71.

Eli Lilly and Company Stock Up 1.9%

LLY stock opened at $1,191.87 on Friday. The stock has a market capitalization of $1.12 trillion, a P/E ratio of 40.00, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45. The firm has a 50-day moving average price of $1,157.76 and a 200-day moving average price of $1,046.57.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The firm’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 36 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above analysts’ expectations near $20.7 billion. Adjusted EPS of $8.38 substantially exceeded the consensus estimate of $6.16. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: Mounjaro sales reportedly surged 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly sales. The performance indicates that demand for Lilly’s diabetes and weight-loss treatments remains strong and is driving the company’s earnings growth. Eli Lilly raises 2026 outlook again as Q2 soars past estimates
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $85 billion-$87 billion from $82 billion-$85 billion. Management also highlighted accelerating adoption of Foundayo, broader Medicare obesity-drug access and progress toward a potential 2027 retatrutide filing. LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
• Positive Sentiment: Analyst optimism remains elevated: Cantor Fitzgerald raised its price target to $1,410 and maintained an “overweight” rating. Coverage also emphasizes that Lilly is widening its lead over Novo Nordisk, whose recent results have raised concerns about competitive momentum. The divide between Eli Lilly and Novo Nordisk is widening
• Neutral Sentiment: Amazon’s planned $50-per-month Medicare access to Wegovy, Zepbound and Foundayo could expand distribution and patient access, but greater retail availability may also increase price competition and payer pressure.
• Negative Sentiment: Several analysts caution that Lilly’s valuation and heavy reliance on GLP-1 products leave the shares vulnerable if demand, manufacturing capacity or competitive conditions weaken.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.